Clinical trials: Aromatase Inhibitor
to Evaluate Letrozole as a Modality for Minimal Ovarian Stimulation in ICSI Cycles .
Letrozole in Assisted Reproductive Technology
Infertility in not a health problem and that infertile couples are not really ill. However, this narrow interpretation of the problem is refuted by the world community.
- Trial name
- NCT02429999
- Testing
- Letrezole plus FSH, Standard protocol for induction of ovulation
- Where
- Egypt
- Volunteers
- 80 people
- Sponsor
- Assiut University
Breast Cancer
Clinical Trial Evaluating the Efficacy and Implementation of an Early Adapted Physical Activity to Prevent and Manage Aromatase Inhibitor-induced Musculoskeletal Pain in Breast Cancer (APIS)
Aromatase inhibitors (AI) are the standard adjuvant hormone therapy for postmenopausal women with hormone-sensitive breast cancer.
- Trial name
- APIS (NCT07295457)
- Testing
- Adapted Physical Activity started early, Adapted Physical Activity begins at the start of hormone therapy
- Where
- 2 sites in France
- Volunteers
- 182 people
- Sponsor
- Hospices Civils de Lyon
Breast Cancer
Letrozole and Goserelin or Leuprolide in Treating Premenopausal Estrogen Receptor-Positive Patients With Stage IV Breast Cancer
RATIONALE: Aromatase inhibitors, such as letrozole, prevent the formation of estradiol, a female hormone. Giving letrozole together with goserelin, leuprolide, or surgery may be an effective treatment in women with…
- Trial name
- NCT00498901
- Testing
- goserelin, letrozole, leuprolide acetate
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- University of Washington
Advanced Breast Cancer
Study to Assess the Safety of Alpelisib Plus Fulvestrant, in Men and Post-menopausal Women With HR-positive, HER2-negative, Advanced Breast Cancer (aBC) With PIK3CA Mutation, Whose Disease Progressed on or After Endocrine Treatment
The purpose of this study was to determine the safety of alpelisib plus fulvestrant in men and post-menopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, advanced or…
- Trial name
- ALPINIST (NCT05631795)
- Testing
- Alpelisib, Fulvestrant
- Where
- 12 sites in India
- Volunteers
- 40 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer
Aromatase Inhibitor Clinical Trial
You are invited to participate in a research study looking at metabolism (breakdown) and effects of aromatase inhibitors. The purpose of this research is to try to identify which women who take an aromatase inhibitor are more…
- Trial name
- NCT00228956
- Testing
- pharmacodynamic analysis
- Where
- 3 sites in United States
- Volunteers
- 500 people
- Sponsor
- National Institute of General Medical Sciences (NIGMS)
Breast Cancer
A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms
Breast cancer is one of the most prevalent cancers with 207,090 new cases of breast cancer and 39,840 deaths in women predicted for 2010 in the United States.
- Trial name
- AIMSS (NCT02874222)
- Testing
- surveys completed by subject
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- United States Naval Medical Center, San Diego
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
Semaglutide and Structured Lifestyle Support to Improve Heart and Blood Vessel Health in Postmenopausal Obese Breast Cancer Survivors Taking Aromatase Inhibitors
This phase IV trial studies whether adding semaglutide to structured lifestyle support improves heart and blood vessel health in postmenopausal obese breast cancer survivors (BCS) who are taking an aromatase inhibitor.
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8
- Trial name
- NCT07769047
- Testing
- Biospecimen Collection, Dual X-ray Absorptiometry, Functional Assessment
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Mayo Clinic
Breast Cancer, Adjuvant Treatment
Evaluating the Use of a Medication 'Switch' vs Guideline-directed Interventions for Relieving Side Effects of Aromatase Inhibitors Among Breast Cancer Patients
Researchers have learned that about 50% of women do not finish the standard 5-year breast cancer treatment with an aromatase inhibitor.
- Conditions
- Breast Cancer, Adjuvant Treatment, Early Stage Breast Cancer
- Trial name
- SWIVEL (NCT07071038)
- Testing
- Switch, Guideline Directed Intervention (GDI)
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Women With Breast Cancer
Effect of Intravaginal Prasterone on Symptoms of Genitourinary Syndrome of Menopause (GSM) in Women in Menopause With Previous Breast Cancer
The goal of this interventional study is to evaluate the effect of Intravaginal Prasterone for the treatment of moderate to severe symptoms of genitourinary syndrome (GSM) due to natural, surgical or treatment-induced menopause…
- Trial name
- PROPOSE (NCT06611514)
- Testing
- Prasterone (DHEA)
- Where
- Italy
- Volunteers
- 95 people
- Sponsor
- European Institute of Oncology
Early-stage Breast Cancer, Hypoactive Sexual Desire Disorder
BRE-06: Study to Increase Tolerance to Aromatase Inhibitors for Patients With Early-Stage Hormone Receptor Positive Breast Cancer Who Developed Hypoactive Sexual Desire Disorder
This study is open to women who have early-stage breast cancer and are on aromatase inhibitor (AI) therapy, and who have hypoactive sexual desire disorder (HSDD).
- Conditions
- Early-stage Breast Cancer, Hypoactive Sexual Desire Disorder, Hormone Receptor Positive Breast Carcinoma, Breast Cancer
- Trial name
- NCT07596212
- Testing
- Aromatase Inhibitors, Bupropion, GnRH agonist
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- University of Illinois Chicago
Breast Cancer
A Randomized Controlled Trial (RCT) to Determine the Efficacy of a Multidisciplinary CBT Based Pain Management Program for the Treatment of Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS) in Breast Cancer Survivors
The purpose of this research is to evaluate the effectiveness of a multidisciplinary pain management program for AIMSS in reducing pain, subjective cognitive complaints, psychological distress, and impaired functional status…
- Trial name
- NCT06831838
- Testing
- Cognitive Behavioral Therapy based Pain Management Program
- Where
- United States
- Volunteers
- 116 people
- Sponsor
- Mayo Clinic
Estrogen Receptor-positive Breast Cancer, Musculoskeletal Complications
A Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS)
E1Z11 is a study to determine whether certain genetic information can predict which breast cancer patients will discontinue treatment with aromatase inhibitors (AIs) due to the development of musculoskeletal symptoms (MSS).
- Conditions
- Estrogen Receptor-positive Breast Cancer, Musculoskeletal Complications, Progesterone Receptor-positive Breast Cancer, Recurrent Breast Cancer
- Trial name
- NCT01824836
- Testing
- anastrozole
- Where
- 2 sites in United States
- Volunteers
- 1,046 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Breast Cancer
Bicalutamide Plus Aromatase Inhibitors in ER(+)/AR(+)/HER2(-) Metastatic Breast Cancer
This study is aim to evaluate the efficacy and safety of bicalutamide and aromatase inhibitor in ER(+)/AR(+)/HER2(-) metastatic breast cancer patients who have disease progression after treatment of an aromatase inhibitor.
- Trial name
- BETTER (NCT02910050)
- Testing
- Bicalutamide, Aromatase Inhibitor
- Where
- China
- Volunteers
- 58 people
- Sponsor
- Xu fei
Metastatic Breast Cancer
Real-world Treatment Patterns and Effectiveness of Palbociclib and AI Therapy
A retrospective observational analysis of de-identified Flatiron Health Analytic Database to describe patient characteristics, treatment patterns and effectiveness of Palbociclib + AI as first-line therapy in HR+/HER2- metastatic…
- Trial name
- NCT04176354
- Testing
- Palbociclib + an aromatase inhibitor, Palbociclib + Letrozole, Letrozole
- Where
- United States
- Volunteers
- 813 people
- Sponsor
- Pfizer
Breast Neoplasms, Cancer Survivor
Self-applied Acupressure for Arthralgia-fatigue-sleep Disturbance in Breast Cancer
This study aims to evaluate the feasibility, acceptability and preliminary effects of self-applied acupressure on arthralgia-fatigue-sleep disturbance symptom cluster in breast cancer survivors receiving aromatase inhibitors.
- Trial name
- NCT04927910
- Testing
- Ture self-acupressure, Usual care
- Where
- China
- Volunteers
- 21 people
- Sponsor
- The Hong Kong Polytechnic University
Recurrent Breast Cancer, Stage IA Breast Cancer
Omega-3 Fatty Acids in Preventing Joint Symptoms in Patients With Stage I-III Breast Cancer Receiving Anastrozole, Exemestane, or Letrozole
This randomized pilot trial studies omega-3 fatty acid in preventing joint symptoms in patients with stage I-III breast cancer receiving anastrozole, exemestane, or letrozole.
- Conditions
- Recurrent Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer
- Trial name
- NCT01478477
- Testing
- omega-3 fatty acid supplement, Clinical assessments, Assessment of therapy complications
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Breast Cancer
Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Participants Resistant to Aromatase Inhibitor Therapy
This is a multicenter, international, randomized, double-blinded, placebo-controlled, Phase II trial. Participants with advanced breast cancer (ABC) or Metastatic Breast Cancer (MBC) who have experienced recurrence or progression…
- Trial name
- NCT01437566
- Testing
- Fulvestrant, GDC-0941, GDC-0980
- Where
- 130 sites in United States, Argentina and 21 more
- Volunteers
- 318 people
- Sponsor
- Genentech, Inc.
Adherence, Medication
Alterations in the Vaginal Microenvironment Using a Non-pharmacological Intervention
Breast cancer patients commonly take medications to reduce the risk of recurrence, including aromatase inhibitors (AIs). AIs can cause significant side effects that reduce patient adherence.
- Trial name
- NCT03739983
- Testing
- Vaginal Renewal Program
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of Wisconsin, Madison
Breast Cancer, Arthralgia
Observational Study to Evaluate Mechanisms of Aromatase Inhibitor Associated Musculoskeletal Symptoms
Early stage hormone receptor positive breast cancer is typically treated with adjuvant endocrine therapy in order to decrease risk of breast cancer recurrence and to improve overall survival from the disease.
- Trial name
- NCT02118636
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Lynn Henry
Miscarriage, Recurrent
Effects of Co-treatment on Endometrial abv3-integrin Expressions in Women With Recurrent Implantation Failure
To compare the abv3-integrin expression in endometrium tissue among RIF women between the GnRH analogue with Aromatase Inhibitor (Group A) , GnRH analogue with progesterone (Group B) and GnRH analogue alone as control group…
- Trial name
- NCT05437471
- Testing
- GNRH Analoge, Duphaston, Letrozole
- Where
- Malaysia
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Universiti Kebangsaan Malaysia Medical Centre